Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

UnitedHealth Group (UNH 1.05%) and Eli Lilly (LLY +1.45%) are two of the largest and most powerful healthcare companies in ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.